secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001104659-25-019467
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M
--------------------------------------------------------------------------------

- APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.
- Combination APG279 (APG777+APG990) Phase 1b vs. DUPIXENT planned for 2025, readout expected H2 2026.
- Full-year 2024 net loss $182.1M (vs. $84.0M in 2023); cash, equivalents and marketable securities $731.1M, runway into Q1 2028.
- Phase 2 APEX trial for APG777 in atopic dermatitis over-enrolled Part A, Part B initiated; 16-week top-line data expected mid-2025.
- R&D expenses $167.9M (up from $68.4M) driven by pipeline advancement and personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/0001104659-25-019467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925019467/tm258007d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-019467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer